PIVOT-006 Study

This trial is recruiting

Clinicaltrials.gov ID:
NCT06111235

Condition:
Non-Muscle Invasive Bladder Cancer
Intermediate-Risk

Contact:
recruitment@cgoncology.com

 

A Study of Intravesical Cretostimogene Grenadenorepvec for Treatment of Patients with Intermediate-Risk (IR), Non-Muscle Invasive Bladder Cancer (NMIBC)

The PIVOT-006
study is testing an investigational drug called cretostimogene for adults with intermediate-risk, non-muscle invasive bladder cancer (NMIBC).

In this study,

cretostimogene will be administered intravesically, meaning it is put directly into the bladder using a thin tube called a catheter.

Patient Eligibility

Study Site Locations

Contact Us